Prior Authorization Bans for Buprenorphine May Not Improve Treatment Retention, Study Finds

State laws designed to eliminate insurance hurdles for life-saving opioid addiction medication may be falling short of their promise, according to research published this week that calls into question a policy strategy nineteen states have embraced.

A study released March 6 in JAMA Health Forum found that bans on prior authorization requirements for buprenorphine—a cornerstone medication for opioid use disorder—did not produce statistically significant improvements in how long patients stayed in treatment. The findings arrive as policymakers across the country look for effective levers to address persistent gaps in addiction care that contribute to more than 50,000 opioid overdose deaths each year.

The Prior Authorization Conundrum

Prior authorization is an administrative gatekeeping process insurers use to control therapeutic costs. Before a patient can receive certain medications, the insurer must approve coverage—a step that can delay or interrupt treatment when individuals need to start therapy, refill prescriptions, or switch medications mid-course.

For buprenorphine, which relieves opioid cravings and withdrawal symptoms, these delays can be particularly consequential. Patients in the early stages of recovery face heightened overdose risk if treatment is interrupted. Even after beginning therapy, approvals typically expire after a limited period, forcing patients and providers to navigate repeated bureaucratic reviews.

Between 2015 and 2022, nineteen states moved to address this friction point by enacting laws that prohibit private insurance plans from requiring prior authorization for buprenorphine. The policy rationale was straightforward: remove administrative barriers, and more people will initiate—and stay on—treatment long enough to achieve recovery milestones.

What the Data Shows

The Weill Cornell Medicine research team, led by Dr. Allison Ju-Chen Hu and senior author Dr. Yuhua Bao, analyzed approximately 23,000 privately insured patients aged 18 to 64 who started new buprenorphine treatment between January 2015 and June 2022.

Retention rates were sobering across the board. Fewer than one-third of patients—30.4 percent—stayed in treatment for at least 180 days without gaps exceeding seven days, the study's primary benchmark. Even when researchers relaxed the definition to allow for longer lapses, less than half (45.7 percent) remained on treatment without interruptions longer than 30 days.

The central finding: patients in states with prior authorization prohibitions showed no statistically significant improvement in retention compared to those in states without such bans.

"As more states enact prior authorization prohibitions to facilitate access to life-saving medications for opioid use disorder, our findings suggest that effective strategies will have to address multiple and interacting barriers," said Dr. Bao, a professor of population health sciences at Weill Cornell. Those barriers include requirements for drug testing, mandatory counseling, and quantity limits on medication—administrative controls that persist even when prior authorization is eliminated.

The Compliance and Enforcement Gap

Dr. Hu, now an assistant professor at Tulane University School of Public Health and Tropical Medicine, emphasized that legislative bans alone may lack teeth.

"Without robust enforcement and monitoring of private insurers' compliance—in addition to the implementation of complementary interventions—legislative bans on prior authorization may have limited impact on closing treatment gaps," she said.

The implication: insurers may comply with the letter of prior authorization bans while maintaining other restrictions that functionally replicate the delays and denials the laws were meant to prevent. Quantity limits that require frequent pharmacy visits, mandatory counseling sessions that patients cannot access due to provider shortages, or urine drug screening requirements that introduce logistical complexity can all undermine continuity of care.

What Works Beyond Policy Levers

The study arrives during a period of tentative progress. The 2023–2024 period saw the largest annual decrease in overdose deaths since 2019, though nearly 55,000 people still died from opioid overdose in 2024, according to CDC provisional data.

Researchers point to broader interventions that may complement—or prove more effective than—narrow administrative reforms:

Provider availability: Expanding the clinician workforce authorized to prescribe buprenorphine remains a bottleneck in many regions. Federal rules eliminating the X-waiver requirement in 2023 removed one barrier, but training gaps and stigma among medical professionals persist.

Stigma reduction: Patients report experiencing judgment from pharmacists, emergency department staff, and even addiction treatment providers when seeking buprenorphine. Cultural shifts within healthcare institutions—alongside public education campaigns—may prove as important as insurance reforms.

Integrated services: Access to counseling, peer support, and wraparound recovery services correlates with better medication adherence. States that pair medication access reforms with investments in behavioral health infrastructure may see stronger outcomes than those focused solely on insurance rule changes.

Dosing flexibility: Research has shown that patients allowed to adjust their buprenorphine doses in consultation with providers—rather than adhering to rigid protocols—demonstrate improved retention. Policies that support individualized treatment plans may outperform one-size-fits-all administrative mandates.

The Road Ahead

The Weill Cornell findings do not suggest that prior authorization bans are counterproductive—only that they are insufficient in isolation. For the millions of Americans struggling with opioid use disorder, treatment access remains a patchwork of overlapping barriers, from insurance red tape to provider shortages to the enduring cultural stigma that frames addiction as a moral failing rather than a medical condition.

Nineteen states have taken a step by eliminating one administrative hurdle. The data now makes clear that closing treatment gaps will require a more comprehensive policy architecture—one that pairs insurance reform with enforcement mechanisms, workforce investment, service integration, and sustained political commitment to treating addiction as the chronic health condition it is.

As Dr. Bao's team noted, the study provides "timely and policy-relevant evidence" at a moment when states are searching for levers that work. The question now is whether policymakers will expand their interventions beyond single-issue reforms to address the layered complexity that keeps too many patients from the medication that could save their lives.